Genincode Share News (GENI)

GENinCode says ROCA recommended as ovarian cancer risk test in England

(Alliance News) - GENinCode PLC on Thursday said its risk of ovarian cancer risk test has been recommended as preferred test in England.

UK shareholder meetings calendar - next 7 days

IN BRIEF: GENinCode gets GBP57,000 in retail offer, well below maximum

GENinCode PLC - biotechnology company focused on prevention of cardiovascular disease - Raises GBP57,378 via a retail offer of 1.1 million shares at a price of 5 pence each. This is in addition to the placing and subscription raised on Thursday last week. At that time, it had said it hoped raise up to GBP1.0 million via the retail offer to existing shareholders. A total of 81.1 million new shares have been issued under all three equity raises, including 67.6 million placing shares and 12.4 million subscription shares. Total gross proceeds are GBP4.1 million. Admission of new shares is expected at the opening bell on January 10, taking the number of GENinCode shares in issue to 177.0 million shares.

IN BRIEF: GENinCode raises GBP4 million via placing and subscription

GENinCode PLC - biotechnology company focused on prevention of cardiovascular disease - Raises GBP4.0 million via a placing and subscription, announced earlier Thursday, at the issue price of 5 pence per share. The issue price represents a discount of 7.1% to the closing middle market price of 5.38p on December 20, the last business day prior to the announcement of the fundraising. The placing was undertaken through an accelerated bookbuild process. A further announcement will be made on December 28 announcing the result of the retail offer under which the company aims to raise up to GBP1.0 million via Bookbuild to existing retail shareholders.

TRADING UPDATES: Aura eyes Tiris expansion; Kavango backs Pambili

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and Tuesday and not separately reported by Alliance News:

EARNINGS: ASA interim profit plummets; Mycelx loss narrows, revenue up

(Alliance News) - The following is a round-up of earnings of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

GENinCode and MedStar collaborate on coronary heart disease testing

(Alliance News) - GENinCode PLC on Wednesday said it will collaborate with MedStar Health for the use of its coronary heart disease diagnostic test.

GENinCode inks partnership with DC's MedStar Health

(Sharecast News) - Predictive generics specialist GENinCode announced a collaboration with MedStar Health on Wednesday - a prominent 10-hospital health system in the Washington, DC area of the United States.

UK shareholder meetings calendar - next 7 days

GENinCode annual loss widens; focuses on US, EU, and NHS in UK

(Alliance News) - GENinCode on Tuesday reported a larger annual loss as cost of sales and administrative expenses ballooned.

TRADING UPDATES: Trident Royalties takes interest in Mexican project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

UK National Health Service to hike use of GENinCode heart disease test

(Alliance News) - GENinCode PLC on Tuesday said the UK National Health Service has set aside a budget to expand use of the company's polygenic testing for heart disease.

AIM WINNERS & LOSERS: Longboat Energy signs Japex joint-venture deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

TRADING UPDATES: GENinCode gets US boost; Cindrigo strikes deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: